Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Revenue: 2012-2025

Historic Revenue for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $211.0 million.

  • Ptc Therapeutics' Revenue rose 7.23% to $211.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 95.40%. This contributed to the annual value of $806.8 million for FY2024, which is 13.97% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Revenue stood at $211.0 million, which was up 17.96% from $178.9 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Revenue ranged from a high of $1.2 billion in Q1 2025 and a low of $116.7 million during Q2 2021.
  • Over the past 3 years, Ptc Therapeutics' median Revenue value was $212.1 million (recorded in 2024), while the average stood at $312.4 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Revenue slumped by 30.58% in 2024, and later spiked by 459.73% in 2025.
  • Over the past 5 years, Ptc Therapeutics' Revenue (Quarterly) stood at $165.2 million in 2021, then grew by 1.32% to $167.4 million in 2022, then spiked by 83.41% to $307.1 million in 2023, then crashed by 30.58% to $213.2 million in 2024, then rose by 7.23% to $211.0 million in 2025.
  • Its last three reported values are $211.0 million in Q3 2025, $178.9 million for Q2 2025, and $1.2 billion during Q1 2025.